Neogenomics Inc
NEO· Nasdaq
NEONeogenomics Inc
Filed Feb 24, 2023 · 10-K · 55 days after period end · 0001077183-23-000023
derived · Computed from the longer spans the company filed.
| Metric | Q4 2022dderived from reported figures | Q4 2021dderived from reported figures | Q4 2020dderived from reported figures | Q4 2019 |
|---|---|---|---|---|
| Revenue | $138.71M | $125.73M | $126.00M | $106.87M |
| Net Income | -$22.69M | -$41.76M | $15.42M | $6.30M |
| EPS Diluted | — | — |
Neogenomics Inc · CIK 1077183 · Engraved from SEC EDGAR
| — |
| $0.06 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
ended Dec 31, 2022 · filed Feb 24, 2023 · 55 d after period end
